Clinical Trials Logo

Chronic Myeloid Leukemia clinical trials

View clinical trials related to Chronic Myeloid Leukemia.

Filter by:

NCT ID: NCT00219765 Terminated - Clinical trials for Chronic Myeloid Leukemia

Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients

Start date: May 2001
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this phase I/II trial is to determine the dose of daunorubicine to be associated with cytarabine and Imatinib for induction therapy in patients with chronic myelogenous leukemia in myeloid acute phase.

NCT ID: NCT00185679 Terminated - Clinical trials for Non-Hodgkin's Lymphoma (NHL)

Haploid Allogeneic Transplant Using the CliniMACS System

Start date: November 2001
Phase: Phase 2
Study type: Interventional

To assess the proportion of patients with donor neutrophil engraftment within 30 days of allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after transplantation.

NCT ID: NCT00101088 Terminated - Clinical trials for Relapsing Chronic Myelogenous Leukemia

Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Start date: April 2005
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of temsirolimus when given with imatinib mesylate in treating patients with chronic myelogenous leukemia. Drugs used in chemotherapy, such as temsirolimus, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving temsirolimus with imatinib mesylate may kill more cancer cells

NCT ID: NCT00023920 Terminated - Clinical trials for Blastic Phase Chronic Myelogenous Leukemia

Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia

Start date: July 2001
Phase: Phase 2
Study type: Interventional

This phase II trial is to see if combining bevacizumab with idarubicin and cytarabine works better in treating patients who have blast phase chronic myelogenous leukemia. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may be an effective treatment for blast phase chronic myelogenous leukemia